Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
about
Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase InhibitorType II Fatty Acid Synthesis Is Essential for the Replication of Chlamydia trachomatisResistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) AntibioticsFabH mutations confer resistance to FabF-directed antibiotics in Staphylococcus aureusHow bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics.Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression.Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria.A Pathogen-Selective Antibiotic Minimizes Disturbance to the Microbiome.Triclosan Resistome from Metagenome Reveals Diverse Enoyl Acyl Carrier Protein Reductases and Selective Enrichment of Triclosan Resistance Genes.Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes.Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.Bacterial fatty acid metabolism in modern antibiotic discovery.Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.Exogenous fatty acid metabolism in bacteria.An Efficient and Economical Assay to Screen for Triclosan Binding to FabI.Therapeutic Targets in Chlamydial Fatty Acid and Phospholipid Synthesis
P2860
Q27683440-E90C82B9-CB21-48E0-B5D9-067AA908E1E8Q27684448-390D2D76-9C5C-49CB-A0C5-599DACC1A8E7Q28069943-6FEBF871-3EF6-4AEF-B23C-9D479E28B4ADQ35105888-EBBFA1A7-1435-41F3-A8DF-D923475CE15DQ35172866-557ACA9D-1C56-4602-89F0-16FD373E8D70Q35618052-A8C8C36E-7B7F-441E-A351-DD114D5A23BBQ36419232-B6F2AD9E-EA5C-4BFD-840D-263800D70F54Q37023140-78C85643-F88F-4E95-94C0-5F7D8CC1BF53Q37220145-D2B53651-5127-4998-8F57-DECDEDF01403Q37425029-0D1CA85F-26DA-4689-82D3-D487E3CEEC04Q38765020-45616042-73BD-4B56-9B63-B432236448ACQ38964523-4C11DDEA-59CA-4F2A-A9B1-717B4E541E8DQ39275601-9A90C599-6B67-437F-83E5-5554BB5E27F7Q39383809-2FE75377-4AAE-4563-9631-A023CB467D0BQ39408643-FBDE6C86-2523-458E-8FEA-3EF9D2646A8CQ53810426-BDE10EAE-D84B-4E04-8EB7-CF3C7C914C1BQ57492054-A2A73ED0-7EAA-4B00-83DE-531392F7A96F
P2860
Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Resistance to AFN-1252 arises ...... rier protein reductase (FabI).
@en
Resistance to AFN-1252 arises ...... acyl carrier protein reductase
@nl
type
label
Resistance to AFN-1252 arises ...... rier protein reductase (FabI).
@en
Resistance to AFN-1252 arises ...... acyl carrier protein reductase
@nl
prefLabel
Resistance to AFN-1252 arises ...... rier protein reductase (FabI).
@en
Resistance to AFN-1252 arises ...... acyl carrier protein reductase
@nl
P2860
P356
P1476
Resistance to AFN-1252 arises ...... rrier protein reductase (FabI)
@en
P2093
Charles O Rock
John B Maxwell
P2860
P304
36261-36271
P356
10.1074/JBC.M113.512905
P407
P50
P577
2013-11-04T00:00:00Z